Hussman Strategic Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.54M | Buy |
21,000
+14,700
| +233% | +$2.81M | 1.05% | 6 |
|
|
2026
Q1 | $1.15M | Buy |
+6,300
| New | +$1.16M | 0.25% | 181 |
|
|
2024
Q4 | – | Sell |
-6,300
| Closed | -$1.22M | – | 245 |
|
|
2024
Q3 | $1.22M | Hold |
6,300
| – | – | 0.3% | 143 |
|
|
2024
Q2 | $1.46M | Hold |
6,300
| – | – | 0.4% | 108 |
|
|
2024
Q1 | $1.36M | Hold |
6,300
| – | – | 0.32% | 121 |
|
|
2023
Q4 | $1.63M | Hold |
6,300
| – | – | 0.37% | 112 |
|
|
2023
Q3 | $1.62M | Hold |
6,300
| – | – | 0.31% | 135 |
|
|
2023
Q2 | $1.79M | Buy |
+6,300
| New | +$1.88M | 0.33% | 136 |
|
|
2022
Q3 | – | Sell |
-21,700
| Closed | -$4.42M | – | 313 |
|
|
2022
Q2 | $4.42M | Buy |
21,700
+3,500
| +19% | +$715K | 0.76% | 22 |
|
|
2022
Q1 | $3.83M | Buy |
18,200
+5,200
| +40% | +$1.13M | 0.74% | 18 |
|
|
2021
Q4 | $3.12M | Buy |
13,000
+5,250
| +68% | +$1.35M | 0.68% | 28 |
|
|
2021
Q3 | $2.19M | Buy |
7,750
+4,650
| +150% | +$1.52M | 0.48% | 75 |
|
|
2021
Q2 | $1.07M | Sell |
3,100
-9,200
| -75% | -$2.79M | 0.22% | 172 |
|
|
2021
Q1 | $3.44M | Hold |
12,300
| – | – | 0.71% | 28 |
|
|
2020
Q4 | $3.01M | Sell |
12,300
-5,600
| -31% | -$1.44M | 0.79% | 20 |
|
|
2020
Q3 | $5.08M | Sell |
17,900
-50
| -0.3% | -$13.9K | 1.34% | 5 |
|
|
2020
Q2 | $4.8M | Buy |
17,950
+5,025
| +39% | +$1.51M | 1.22% | 4 |
|
|
2020
Q1 | $4.09M | Buy |
12,925
+2,925
| +29% | +$888K | 1.1% | 5 |
|
|
2019
Q4 | $2.97M | Buy |
10,000
+2,500
| +33% | +$694K | 0.94% | 27 |
|
|
2019
Q3 | $1.75M | Sell |
7,500
-2,500
| -25% | -$582K | 0.49% | 80 |
|
|
2019
Q2 | $2.34M | Hold |
10,000
| – | – | 0.65% | 59 |
|
|
2019
Q1 | $2.36M | Buy |
10,000
+2,500
| +33% | +$787K | 0.58% | 63 |
|
|
2018
Q4 | $2.26M | Buy |
+7,500
| New | +$2.39M | 0.55% | 78 |
|
|
2018
Q3 | – | Sell |
-5,000
| Closed | -$1.45M | – | 222 |
|
|
2018
Q2 | $1.45M | Sell |
5,000
-5,000
| -50% | -$1.41M | 0.39% | 115 |
|
|
2018
Q1 | $2.74M | Buy |
+10,000
| New | +$3.1M | 0.76% | 57 |
|
|
2017
Q3 | – | Sell |
-10,000
| Closed | -$2.71M | – | 205 |
|
|
2017
Q2 | $2.71M | Buy |
10,000
+9,750
| +3,900% | +$2.58M | 0.6% | 74 |
|
|
2017
Q1 | $68K | Sell |
250
-100
| -29% | -$28.3K | 0.02% | 175 |
|
|
2016
Q4 | $99K | Buy |
+350
| New | +$104K | 0.02% | 146 |
|
|
2013
Q4 | – | Sell |
-75,000
| Closed | -$18.1M | – | 201 |
|
|
2013
Q3 | $18.1M | Buy |
75,000
+25,000
| +50% | +$5.6M | 0.99% | 40 |
|
|
2013
Q2 | $10.8M | Buy |
+50,000
| New | +$10.7M | 0.49% | 88 |
|
Other funds holding BIIB
Hussman Strategic Advisors's BIIB Position: Q2 2026 in Review
Hussman Strategic Advisors increased its Biogen (BIIB) stake by 233% in Q2 2026, buying an estimated $2.81M and bringing the position to 21,000 shares worth $4.54M. The position accounts for 1.05% of the portfolio, ranked #6.
Hussman Strategic Advisors first reported a position in BIIB in Q2 2013 and has held it in 30 quarters since. The position peaked at $18.1M in Q3 2013. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Hussman Strategic Advisors held 21,000 shares of Biogen worth $4.54M as of Q2 2026.
- Hussman Strategic Advisors bought 14,700 Biogen shares in Q2 2026, an estimated $2.81M.
- Biogen made up 1.05% of Hussman Strategic Advisors's portfolio in Q2 2026, its #6 holding.
- Hussman Strategic Advisors first reported a position in Biogen in Q2 2013 and has held it in 30 quarters since.
- Hussman Strategic Advisors's Biogen position peaked at $18.1M in Q3 2013.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.